Sepsis contributes to nearly 1 in 3 U.S. hospital deaths. SeaStar’s therapy gets FDA breakthrough designation.

FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

SeaStar Medical Receives FDA's Medical Breakthrough Device Designation For Its Selective Cytopheretic Device Therapy To Treat Hyperinflammation

MarketBeat rates ICU Medical stock Moderate Buy with USD 200 target

SeaStar Medical Company Profile & Introduction

12 Health Care Stocks Moving In Monday's Intraday Session

SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds

SeaStar Medical’s deal would give investors rights to buy up to 1.71 million shares.

Will Product Recalls Change ICU Medical (ICUI) Stock Narrative

SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026

12 Health Care Stocks Moving In Friday's Intraday Session

New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical’s SCD Therapy for Acute Kidney Injury (AKI)

SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026

SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy

ICU Medical (ICUI) Stock May Be 26% Undervalued On Cash Flow